Symbols / IVVD Stock $0.99 -2.94% Invivyd, Inc.

Healthcare • Biotechnology • United States • NGM
IVVD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NGM · United States
Market Cap 291.66M
Enterprise Value 116.13M
Income -77.60M
Sales 55.87M
FCF (ttm) -50.10M
Book/sh 0.72
Cash/sh 0.62
Employees 122
Insider 10d —
IPO Aug 06, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.71
PEG —
P/S 5.22
P/B 1.38
P/C —
EV/EBITDA -1.43
EV/Sales 2.08
Quick Ratio 6.20
Current Ratio 6.47
Debt/Eq 4.25
LT Debt/Eq —
EPS (ttm) -0.29
EPS next Y -0.58
EPS Growth —
Revenue Growth 21.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-13
Earnings (prior) 2026-05-14
ROA -29.59%
ROE -60.34%
ROIC —
Gross Margin 92.94%
Oper. Margin -3.14%
Profit Margin -138.90%
Shs Outstand 294.61M
Shs Float 214.30M
Insider Own 7.07%
Instit Own 83.87%
Short Float 11.60%
Short Ratio 10.43
Short Interest 30.93M
52W High 3.07
vs 52W High -67.75%
52W Low 0.48
vs 52W Low 104.97%
Beta 0.63
Impl. Vol. 3.13%
Rel Volume 1.73
Avg Volume 3.12M
Volume 5.39M
Target (mean) $10.00
Tgt Median $10.00
Tgt Low $10.00
Tgt High $10.00
# Analysts 3
Recom Strong_buy
Prev Close $1.02
Price $0.99
Change -2.94%
About

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.00
Mean price target
2. Current target
$0.99
Latest analyst target
3. DCF / Fair value
$-3.06
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.99
Low
$10.00
High
$10.00
Mean
$10.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-09 reit BTIG Buy → Buy $10
2026-06-01 reit BTIG Buy → Buy $10
2026-05-18 reit BTIG Buy → Buy $10
2026-02-26 reit BTIG Buy → Buy $10
2025-12-23 reit BTIG Buy → Buy $10
2025-12-22 init BTIG — → Buy $10
2025-11-25 down D. Boral Capital Buy → Hold —
2025-11-03 main HC Wainwright & Co. Buy → Buy $10
2025-10-31 main HC Wainwright & Co. Buy → Buy $10
2025-10-06 main D. Boral Capital Buy → Buy $2
2025-10-06 init Cantor Fitzgerald — → Overweight $10
2025-08-27 reit HC Wainwright & Co. Buy → Buy $5
2025-08-25 main D. Boral Capital Buy → Buy $1
2025-08-19 main D. Boral Capital Buy → Buy $3
2025-08-15 main D. Boral Capital Buy → Buy $3
2025-06-26 reit HC Wainwright & Co. Buy → Buy $5
2025-06-26 main D. Boral Capital Buy → Buy $9
2025-05-28 main HC Wainwright & Co. Buy → Buy $5
2025-05-16 main D. Boral Capital Buy → Buy $9
2025-03-26 reit HC Wainwright & Co. Buy → Buy $10
News
RSS: Latest IVVD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-18 DUKE WILLIAM E. JR. Chief Financial Officer — 40,627 $1.54 $63,350
2026-02-18 ANDERSEN JILL Officer — 67,710 $1.54 $105,581
2026-02-18 ALLEN ROBERT D III Officer — 37,581 $1.54 $58,600
2026-02-18 GREEN JULIE Officer — 40,627 $1.54 $63,350
2026-02-18 LEE EDWARD TIMOTHY Officer — 40,627 $1.54 $63,350
2026-02-13 DUKE WILLIAM E. JR. Chief Financial Officer — 99,000 — —
2026-02-13 ANDERSEN JILL Officer — 165,000 — —
2026-02-13 ALLEN ROBERT D III Officer — 99,000 — —
2026-02-13 GREEN JULIE Officer — 99,000 — —
2026-02-13 LEE EDWARD TIMOTHY Officer — 99,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
53.43
+110.47%
25.38
0.00
0.00
Operating Revenue
53.43
+110.47%
25.38
0.00
0.00
Cost Of Revenue
3.75
+131.58%
1.62
0.00
—
Reconciled Cost Of Revenue
3.75
+131.58%
1.62
0.00
—
Gross Profit
49.68
+109.03%
23.77
0.00
—
Operating Expense
105.24
-47.55%
200.64
-3.44%
207.78
-8.17%
226.26
Research And Development
38.31
-72.09%
137.25
-13.49%
158.66
-11.47%
179.21
Selling General And Administration
66.93
+5.59%
63.39
+29.03%
49.12
+4.42%
47.04
General And Administrative Expense
66.93
+5.59%
63.39
+29.03%
49.12
+4.42%
47.04
Salaries And Wages
31.26
+4.50%
29.91
+9.46%
27.32
+29.17%
21.15
Other Gand A
35.67
+6.56%
33.48
+53.56%
21.80
-15.79%
25.89
Total Expenses
108.99
-46.12%
202.26
-2.66%
207.78
-8.17%
226.26
Operating Income
-55.56
+68.59%
-176.88
+14.87%
-207.78
+8.17%
-226.26
Total Operating Income As Reported
-55.56
+68.59%
-176.88
+16.87%
-212.76
+14.22%
-248.03
EBITDA
-53.45
+69.24%
-173.76
+15.55%
-205.75
+8.88%
-225.80
Normalized EBITDA
-53.45
+69.24%
-173.76
+13.46%
-200.78
+1.59%
-204.02
Reconciled Depreciation
2.11
-32.32%
3.11
+53.50%
2.03
+338.96%
0.46
EBIT
-55.56
+68.59%
-176.88
+14.87%
-207.78
+8.17%
-226.26
Total Unusual Items
—
0.00
+100.00%
-4.97
+77.15%
-21.77
Total Unusual Items Excluding Goodwill
—
0.00
+100.00%
-4.97
+77.15%
-21.77
Special Income Charges
—
0.00
+100.00%
-4.97
-13.07%
-4.40
Other Special Charges
—
—
4.97
+13.07%
4.40
Net Income
-52.49
+69.11%
-169.93
+14.46%
-198.64
+17.68%
-241.32
Pretax Income
-52.49
+69.11%
-169.93
+14.46%
-198.64
+17.68%
-241.32
Other Income Expense
3.07
-55.82%
6.95
-23.95%
9.14
+160.69%
-15.06
Other Non Operating Income Expenses
3.07
-55.82%
6.95
-50.75%
14.12
+110.23%
6.71
Gain On Sale Of Security
—
—
—
-17.37
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-52.49
+69.11%
-169.93
+14.46%
-198.64
+17.68%
-241.32
Net Income From Continuing Operation Net Minority Interest
-52.49
+69.11%
-169.93
+14.46%
-198.64
+17.68%
-241.32
Net Income From Continuing And Discontinued Operation
-52.49
+69.11%
-169.93
+14.46%
-198.64
+17.68%
-241.32
Net Income Continuous Operations
-52.49
+69.11%
-169.93
+14.46%
-198.64
+17.68%
-241.32
Normalized Income
-52.49
+69.11%
-169.93
+12.26%
-193.67
+11.79%
-219.54
Net Income Common Stockholders
-52.49
+69.11%
-169.93
+14.46%
-198.64
+17.68%
-241.32
Diluted EPS
-0.30
+79.02%
-1.43
+20.99%
-1.81
+18.83%
-2.23
Basic EPS
-0.30
+79.02%
-1.43
+20.99%
-1.81
+18.83%
-2.23
Basic Average Shares
172.21
+45.26%
118.56
+8.24%
109.53
+1.16%
108.27
Diluted Average Shares
172.21
+45.26%
118.56
+8.24%
109.53
+1.16%
108.27
Diluted NI Availto Com Stockholders
-52.49
+69.11%
-169.93
+14.46%
-198.64
+17.68%
-241.32
Line Item Trend 2022-12-31 2021-12-31
Total Assets
383.17
—
Current Assets
376.92
—
Cash Cash Equivalents And Short Term Investments
371.99
—
Cash And Cash Equivalents
92.08
—
Other Short Term Investments
279.92
+469.00%
49.19
Receivables
0.38
—
Accounts Receivable
—
—
Accrued Interest Receivable
0.38
—
Inventory
—
—
Finished Goods
—
—
Prepaid Assets
4.55
—
Other Current Assets
—
—
Total Non Current Assets
6.25
—
Net PPE
6.06
—
Gross PPE
6.06
—
Other Properties
6.06
—
Other Non Current Assets
0.19
—
Total Liabilities Net Minority Interest
27.20
—
Current Liabilities
25.03
—
Payables And Accrued Expenses
17.44
—
Payables
1.52
—
Accounts Payable
1.52
—
Current Accrued Expenses
15.93
—
Pensionand Other Post Retirement Benefit Plans Current
5.99
—
Current Debt And Capital Lease Obligation
1.56
—
Current Capital Lease Obligation
1.56
—
Other Current Liabilities
0.04
—
Total Non Current Liabilities Net Minority Interest
2.17
—
Long Term Debt And Capital Lease Obligation
2.17
—
Long Term Capital Lease Obligation
2.17
—
Tradeand Other Payables Non Current
—
—
Other Non Current Liabilities
0.00
-91.67%
0.01
Preferred Securities Outside Stock Equity
—
0.00
Stockholders Equity
355.97
—
Common Stock Equity
355.97
—
Capital Stock
0.01
—
Common Stock
0.01
—
Preferred Stock
0.00
—
Share Issued
109.04
—
Ordinary Shares Number
109.04
—
Treasury Shares Number
0.00
-100.00%
0.47
Additional Paid In Capital
889.66
—
Retained Earnings
-533.43
—
Gains Losses Not Affecting Retained Earnings
-0.27
—
Treasury Stock
0.00
0.00
Other Equity Adjustments
-0.27
—
Total Equity Gross Minority Interest
355.97
—
Total Capitalization
355.97
—
Working Capital
351.89
—
Invested Capital
355.97
—
Total Debt
3.72
—
Capital Lease Obligations
3.72
—
Net Tangible Assets
355.97
—
Tangible Book Value
355.97
—
Dueto Related Parties Non Current
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-58.13
+65.90%
-170.49
+1.54%
-173.16
+21.28%
-219.99
Cash Flow From Continuing Operating Activities
-58.13
+65.90%
-170.49
+1.54%
-173.16
+21.28%
-219.99
Net Income From Continuing Operations
-52.49
+69.11%
-169.93
+14.46%
-198.64
+17.68%
-241.32
Depreciation Amortization Depletion
2.11
-32.32%
3.11
+53.50%
2.03
+338.96%
0.46
Depreciation
2.11
-32.32%
3.11
+53.50%
2.03
+338.96%
0.46
Depreciation And Amortization
2.11
-32.32%
3.11
+53.50%
2.03
+338.96%
0.46
Other Non Cash Items
0.30
—
—
—
Stock Based Compensation
11.64
-41.16%
19.79
+5.90%
18.68
-13.69%
21.65
Operating Gains Losses
—
—
—
17.37
Gain Loss On Investment Securities
—
—
—
17.37
Change In Working Capital
-19.69
+16.08%
-23.47
-498.56%
5.89
+136.50%
-16.13
Change In Receivables
-3.34
+69.40%
-10.91
0.00
—
Changes In Account Receivables
-3.34
+69.40%
-10.91
0.00
—
Change In Inventory
-0.37
+98.50%
-24.89
0.00
—
Change In Prepaid Assets
12.92
+305.78%
3.19
+116.86%
-18.89
-192.76%
20.37
Change In Payables And Accrued Expense
-27.64
-343.00%
11.37
-55.63%
25.63
+165.45%
-39.17
Change In Accrued Expense
-30.85
-444.66%
8.95
-53.29%
19.16
+154.96%
-34.87
Change In Payable
3.21
+32.52%
2.42
-62.56%
6.47
+250.49%
-4.30
Change In Account Payable
3.21
+32.52%
2.42
-62.56%
6.47
+250.49%
-4.30
Change In Other Current Assets
-0.08
-154.61%
0.14
+781.25%
0.02
-99.48%
3.11
Change In Other Current Liabilities
-1.20
+49.60%
-2.37
-172.84%
-0.87
-99.31%
-0.44
Investing Cash Flow
-0.15
-10.71%
-0.14
-100.05%
280.68
+221.68%
-230.67
Cash Flow From Continuing Investing Activities
-0.15
-10.71%
-0.14
-100.05%
280.68
+221.68%
-230.67
Net PPE Purchase And Sale
-0.15
-10.71%
-0.14
+77.24%
-0.61
+63.93%
-1.71
Purchase Of PPE
-0.15
-10.71%
-0.14
+77.24%
-0.61
+63.93%
-1.71
Capital Expenditure
-0.15
-10.71%
-0.14
+77.24%
-0.61
+63.93%
-1.71
Net Investment Purchase And Sale
—
0.00
-100.00%
281.30
+222.86%
-228.96
Purchase Of Investment
—
0.00
+100.00%
-91.20
+69.39%
-297.96
Sale Of Investment
—
0.00
-100.00%
372.50
+439.86%
69.00
Financing Cash Flow
215.63
+448.24%
39.33
+3663.73%
1.04
+106.52%
0.51
Cash Flow From Continuing Financing Activities
215.63
+448.24%
39.33
+3663.73%
1.04
+106.52%
0.51
Net Common Stock Issuance
215.30
+448.05%
39.28
+3928600.00%
-0.00
+75.00%
-0.00
Common Stock Payments
-0.63
0.00
+100.00%
-0.00
+75.00%
-0.00
Repurchase Of Capital Stock
-0.63
0.00
+100.00%
-0.00
+75.00%
-0.00
Proceeds From Stock Option Exercised
0.67
+3.42%
0.64
-46.19%
1.20
+134.31%
0.51
Net Other Financing Charges
-0.34
+43.72%
-0.60
-300.67%
-0.15
—
Changes In Cash
157.34
+219.83%
-131.30
-220.94%
108.56
+124.12%
-450.15
Effect Of Exchange Rate Changes
0.00
-100.00%
0.01
0.00
—
Beginning Cash Position
69.35
-65.44%
200.64
+117.91%
92.08
-83.02%
542.22
End Cash Position
226.69
+226.88%
69.35
-65.44%
200.64
+117.91%
92.08
Free Cash Flow
-58.29
+65.84%
-170.63
+1.81%
-173.78
+21.61%
-221.69
Amortization Of Securities
—
0.00
+100.00%
-1.12
+44.54%
-2.02
Common Stock Issuance
215.93
+449.66%
39.28
0.00
0.00
Issuance Of Capital Stock
215.93
+449.66%
39.28
0.00
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category